https://feeds.newsfilecorp.com/company/7197 Latest news from Appili Therapeutics Inc., as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Tue, 29 Sep 2026 10:38:42 -0400 https://images.newsfilecorp.com/logos/7197.jpg https://feeds.newsfilecorp.com/company/7197 https://www.newsfilecorp.com/release/316490/Appili-Therapeutics-Announces-Transfer-to-NEX Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, announces that it has applied to voluntarily delist its Class A common shares (the "Common Shares") from the Toronto Stock Exchange (the "TSX") and transfer its listing to the NEX Board of the TSX Venture Exchange (the "NEX") as a result of the Company's failure to meet...<img src="https://api.newsfilecorp.com/newsinfo/316490/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Tue, 29 Sep 2026 08:30:00 -0400 en https://www.newsfilecorp.com/release/316490 https://www.newsfilecorp.com/release/309716/Appili-Therapeutics-Reports-Financial-and-Operational-Results-for-First-Quarter-of-Fiscal-Year-2027 Appili adopts a new business strategy that focuses on the biodefence sector Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars...<img src="https://api.newsfilecorp.com/newsinfo/309716/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Fri, 14 Aug 2026 17:00:00 -0400 en https://www.newsfilecorp.com/release/309716 Appili adopts a new business strategy that focuses on the biodefence sector